AVEO Pharmaceuticals - Top 20 VC deals of 2007

Company: AVEO Pharmaceuticals
Based: Cambridge, MA
Amount: $58.5
Investors: Bessemer Venture Partners, Biogen Idec New Ventures, Flagship Ventures, GE Equity, Greylock Partners, Highland Capital Partners, Individuals, MPM Capital, Merck & Co., Merlin Nexus, Mitsubishi UFJ Capital Co., Oxford Bioscience Partners, Prospect Venture Partners, Schering-Plough, Undisclosed Corporate Investor, Undisclosed Investor, Venrock Associates

Scoop: AVEO is developing a number of cancer therapies. The company's first product is AV-299, a monoclonal antibody targeting Hepatocyte Growth Factor (HGF). An IND is expected shortly. Recently, OSI Pharmaceuticals and AVEO inked a deal to discover and develop small molecules. The companies hope to develop therapies that target the underlying mechanisms of epithelial-mesenchymal transition in cancer.

More News:
OSI, AVEO sign small molecules pact. Report
AVEO designs better mice to trap better therapies. Report
AVEO gains $53M in financing. Report

AVEO Pharmaceuticals - Top 20 VC deals of 2007
Read more on

Suggested Articles

Karen DeSalvo's appointment is the latest in a string of hires that deepen the tech giant’s investment in and focus on healthcare.

Spring Bank’s hepatitis B drug, given in tandem with Gilead’s Vemlidy, tamped down on chronic disease in 23% of patients in a phase 2 study.

Verseau will use the money to start testing its macrophage checkpoint modulators in humans.